| Assessment Status | Rapid Review Complete |
| HTA ID | 25004 |
| Drug | Ruxolitinib |
| Brand | Opzelura® |
| Indication | Ruxolitinib (Opzelura®) is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. |
| Assessment Process | |
| Rapid review commissioned | 09/01/2025 |
| Rapid review completed | 17/02/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ruxolitinib cream for this indication compared with the current standard of care. |
| Full HTA commissioned by the HSE | 26/02/2025 |
The company has not submitted a HTA dossier to the NCPE; therefore the cost-effectiveness of the technology could not be proven.